ENXTAM:CURE

Stock Analysis Report

Executive Summary

Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally.

Snowflake

Fundamentals

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Curetis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

CURE

-1.8%

NL Medical Equipment

0.6%

NL Market


1 Year Return

-89.4%

CURE

19.1%

NL Medical Equipment

7.0%

NL Market

Return vs Industry: CURE underperformed the Dutch Medical Equipment industry which returned 19.1% over the past year.

Return vs Market: CURE underperformed the Dutch Market which returned 7% over the past year.


Shareholder returns

CUREIndustryMarket
7 Day-4.2%-1.8%0.6%
30 Day-46.6%-1.5%-1.6%
90 Day-53.5%-0.9%-1.4%
1 Year-89.4%-89.4%21.0%19.1%11.7%7.0%
3 Year-95.0%-95.0%64.1%55.6%42.4%26.6%
5 Yearn/a130.8%108.8%70.9%36.7%

Price Volatility Vs. Market

How volatile is Curetis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Curetis undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: CURE (€0.32) is trading below our estimate of fair value (€1.12)

Significantly Undervalued: CURE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CURE is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CURE is unprofitable, so we can't compare its PE Ratio to the Dutch market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CURE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CURE is overvalued based on its PB Ratio (331.1x) compared to the XE Medical Equipment industry average (3.4x).


Next Steps

Future Growth

How is Curetis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

43.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CURE's forecast earnings growth is above the savings rate (0.4%).

Earnings vs Market: Insufficient data to determine if CURE's earnings are forecast to grow faster than the Dutch market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CURE's revenue (43.2% per year) is forecast to grow faster than the Dutch market (5.9% per year).

High Growth Revenue: CURE's revenue (43.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CURE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Curetis performed over the past 5 years?

-35.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CURE is unprofitable, and losses have increased over the past 5 years at a rate of -35% per year.

Accelerating Growth: Unable to compare CURE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (4.3%).


Return on Equity

High ROE: CURE has a negative Return on Equity (-105731.82%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CURE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CURE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Curetis's financial position?


Financial Position Analysis

Short Term Liabilities: CURE's short term assets (€13.9M) exceeds its short term liabilities (€6.2M)

Long Term Liabilities: CURE's short term assets (13.9M) do not cover its long term liabilities (20.5M)


Debt to Equity History and Analysis

Debt Level: CURE's debt to equity ratio (104477.3%) is considered high

Reducing Debt: CURE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: CURE has a high level of physical assets or inventory.

Debt Coverage by Assets: CURE's debt is not covered by short term assets (assets are 0.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CURE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Curetis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%6.0%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CURE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CURE's dividend in 3 years as they are not forecast to pay a notable one for the Dutch market.


Next Steps

Management

What is the CEO of Curetis's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Oliver Schacht (48yo)

8.5yrs

Tenure

€318,000

Compensation

Dr. Oliver Schacht, Ph.D., has been the Chief Executive Officer at Curetis N.V. since April 2011 and serves as its Member of Management Board and Managing Director. He co-founded Epigenomics AG and also se ...


CEO Compensation Analysis

Compensation vs. Market: Oliver's total compensation ($USD350.45K) is about average for companies of similar size in the Dutch market ($USD478.91K).

Compensation vs Earnings: Oliver's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.0yrs

Average Tenure

50yo

Average Age

Experienced Management: CURE's management team is considered experienced (4 years average tenure).


Board Age and Tenure

3.9yrs

Average Tenure

65yo

Average Age

Experienced Board: CURE's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Oliver Schacht (48yo)

    CEO, MD & Member of Management Board

    • Tenure: 8.5yrs
    • Compensation: €318.00k
  • Achim Plum (51yo)

    Chief Business Officer

    • Tenure: 0yrs
    • Compensation: €280.00k
  • Johannes Bacher (50yo)

    COO & Member of Management Board

    • Tenure: 4yrs
    • Compensation: €292.00k
  • Heiko Schorr

    Director of Finance

    • Tenure: 7.6yrs
  • Helmut Hilbert

    Head of Business Development

    • Tenure: 0yrs
  • Bernd Bleile

    General Counsel

    • Tenure: 3.7yrs
  • Andreas Posch

    Managing Director of Ares Genetics

    • Tenure: 0yrs
  • Chris Emery

    President & CEO of Curetis USA Inc

    • Tenure: 1.1yrs

Board Members

  • Bill Rhodes (65yo)

    Chairman of Supervisory Board

    • Tenure: 3.9yrs
    • Compensation: €105.00k
  • Mario Crovetto (65yo)

    Member of Supervisory Board

    • Tenure: 3.9yrs
    • Compensation: €64.00k
  • Prabhavathi Fernandes (70yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €53.00k
  • Werner Schäfer (71yo)

    Vice-Chairman of the Supervisory Board

    • Tenure: 3.9yrs
    • Compensation: €83.00k
  • Jean-Louis Vincent

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Rudy DeKeyser (57yo)

    Member of Supervisory Board

    • Tenure: 4.9yrs
  • Robin Patel

    Member of U.S. Scientific Advisory Board

    • Tenure: 0yrs
  • Reno Frei

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Laurent Poirel

    Member of Medical Advisory Board

    • Tenure: 3.5yrs
  • Melissa Miller

    Member of U.S. Scientific Advisory Board

    • Tenure: 2.5yrs

Company Information

Curetis N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Curetis N.V.
  • Ticker: CURE
  • Exchange: ENXTAM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €8.263m
  • Shares outstanding: 25.62m
  • Website: https://www.curetis.com

Number of Employees


Location

  • Curetis N.V.
  • Max-Eyth-Strasse 42
  • Holzgerlingen
  • Baden-Württemberg
  • 71088
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CUREENXTAM (Euronext Amsterdam)YesOrdinary SharesNLEURNov 2015
CNYDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2015
0RDDLSE (London Stock Exchange)YesOrdinary SharesGBEURNov 2015
CUREABATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURNov 2015

Biography

Curetis N.V., a commercial-stage molecular diagnostics company, provides solutions for laboratories, pharma-companies, and public hospitals in Germany and internationally. The company develops, manufacture ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 21:44
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.